1 On 1 August 2007 Patronic purchased 18 million of a total of 24 million equity shares in Sardonic. The acquisition was through a share exchange of two shares in Patronic for every three shares in Sardonic. Both companies have shares with a par value of £1 each. The market price of Patronic’s shares at 1 August 2007 was £5·75 per share. Patronic will also pay in cash on 31 July 2009 (two years after acquisition) £2·42 per acquired share of Sardonic. Patronic’s cost of capital is 10% per annum. The reserves of Sardonic on 1 April 2007 were £69 million. Patronic has held an investment of 30% of the equity shares in Acerbic for many years. The summarised profit and loss accounts for the three companies for the year ended 31 March 2008 are: Patronic Sardonic Acerbic £’000 £’000 £’000 Turnover 150,000 78,000 80,000 Cost of sales (94,000) (51,000) (60,000) –––––––– ––––––– ––––––– Gross profit 56,000 27,000 20,000 Distribution costs (7,400) (3,000) (3,500) Administrative expenses (12,500) (6,000) (6,500) –––––––– ––––––– ––––––– Operating profit 36,100 18,000 10,000 Finance costs (note (ii)) (2,000) (900) nil –––––––– ––––––– ––––––– Profit before tax 34,100 17,100 10,000 Tax (10,400) (3,600) (4,000) –––––––– ––––––– ––––––– Profit for the year 23,700 13,500 6,000 –––––––– ––––––– ––––––– The following information is relevant: (i) The fair values of the net assets of Sardonic at the date of acquisition were equal to their carrying amounts with the exception of property and plant. Property and plant had fair values of £4·1 million and £2·4 million respectively in excess of their carrying amounts. The increase in the fair value of the property would create additional depreciation of £200,000 in the consolidated financial statements in the post acquisition period to 31 March 2008 and the plant had a remaining life of four years (straight-line depreciation) at the date of acquisition of Sardonic. All depreciation is treated as part of cost of sales. The fair values have not been reflected in Sardonic’s financial statements. No fair value adjustments were required on the acquisition of Acerbic. (ii) The finance costs of Patronic do not include the finance cost on the deferred consideration. (iii) Prior to its acquisition, Sardonic had been a good customer of Patronic. In the year to 31 March 2008, Patronic sold goods at a selling price of £1·25 million per month to Sardonic both before and after its acquisition. Patronic made a profit of 20% on the cost of these sales. At 31 March 2008 Sardonic still held stock of £3 million (at cost to Sardonic) of goods purchased in the post acquisition period from Patronic. (iv) The goodwill of Sardonic should be amortised over a nine-year life with time apportionment in the year of acquisition. The goodwill in Acerbic was deemed to have an indefinite life and was not impaired at 31 March 2008. (v) All items in the above profit and loss accounts are deemed to accrue evenly over the year. (vi) Ignore deferred tax.
Required: (a) Calculate the goodwill arising on the acquisition of Sardonic at 1 August 2007. (6 marks) (b) Prepare the consolidated profit and loss account for the Patronic Group for the year ended 31 March 2008. Note: assume that the investment in Acerbic has been accounted for using the equity method since its acquisition. (15 marks) (c) At 31 March 2008 the other equity shares (70%) in Acerbic were owned by many separate investors. Shortly after this date Spekulate (a company unrelated to Patronic) accumulated a 60% interest in Acerbic by buying shares from the other shareholders. In May 2008 a meeting of the board of directors of Acerbic was held at which Patronic lost its seat on Acerbic’s board. Required: Explain, with reasons, the accounting treatment Patronic should adopt for its investment in Acerbic when it prepares its financial statements for the year ending 31 March 2009. (4 marks) (25 marks) 1 (a) Cost of control in Sardonic: £’000 £’000 Consideration Shares (18,000 x 2/3 x £5.75) 69,000 Deferred payment (18,000 x 2.42/1.21 (see below)) 36,000 –––––––– 105,000 Less Equity shares 24,000 Pre-acquisition reserves: At 1 April 2007 69,000 To date of acquisition (13,500 x 4/12) 4,500 Fair value adjustments (4,100 + 2,400) 6,500 –––––––– 104,000 x 75% (78,000) –––––––– Goodwill 27,000 –––––––– £1 compounded for two years at 10% would be worth £1·21. The acquisition of 18 million out of a total of 24 million equity shares is a 75% interest. (b) Patronic Group Consolidated profit and loss account for the year ended 31 March 2008 £’000 £’000 Turnover (150,000 + (78,000 x 8/12) – (1,250 x 8 months intra group)) 192,000 Cost of sales (w (i)) (119,100) –––––––– Gross profit 72,900 Distribution costs (7,400 + (3,000 x 8/12)) (9,400) Administrative expenses (12,500 + (6,000 x 8/12)) (16,500) Amortisation of goodwill (27,000/9 years x 8/12) (2,000) –––––––– Operating profit 45,000 Finance costs (w (ii)) (5,000) Share of profit from associate (10,000 x 30%) 3,000 –––––––– Profit before tax 43,000 Tax – group (10,400 + (3,600 x 8/12)) (12,800) – associate (4,000 x 30%) (1,200) (14,000) –––––––– –––––––– Profit after tax 29,000 Minority interest (w (iii)) (2,100) –––––––– Profit for the year 26,900 –––––––– (c) An associate is defined by FRS 9 Associates and Joint Ventures as an investment over which an investor has significant influence. There are several indicators of significant influence, but the most important are usually considered to be a holding of 20% or more of the voting shares and board representation. Therefore it was reasonable to assume that the investment in Acerbic (at 31 March 2008) represented an associate and was correctly accounted for under the equity accounting method. The current position (from May 2008) is that although Patronic still owns 30% of Acerbic’s shares, Acerbic has become a subsidiary of Spekulate as it has acquired 60% of Acerbic’s shares. Acerbic is now under the control of Spekulate (part of the definition of being a subsidiary), therefore it is difficult to see how Patronic can now exert significant influence over Acerbic. The fact that Patronic has lost its seat on Acerbic’s board seems to reinforce this point. In these circumstances the investment in Acerbic falls to be treated under FRS 26 Financial Instruments: Recognition and Measurement. It will cease to be equity accounted from the date of loss of significant influence. Its carrying amount at that date will be its initial recognition value under FRS 26 and thereafter it will be carried at fair value. Workings (i) Cost of sales £’000 £’000 Patronic 94,000 Sardonic (51,000 x 8/12) 34,000 Intra group purchases (1,250 x 8 months) (10,000) Additional depreciation: plant (2,400/ 4 years x 8/12) 400 property (per question) 200 600 –––– Unrealised profit in stock (3,000 x 20/120) 500 –––––––– 119,100 –––––––– Note: for both sales and cost of sales, only the post acquisition intra group trading should be eliminated. (ii) Finance costs £’000 Patronic per question 2,000 Unwinding interest – deferred consideration (36,000 x 10% x 8/12) 2,400 Sardonic (900 x 8/12) 600 –––––– 5,000 –––––– (iii) Minority interest Sardonic’s post acquisition profit (13,500 x 8/12) 9,000 Less post acquisition additional depreciation (w (i)) (600) –––––– 8,400 x 25% = 2,100 |